Weitere Artikel dieser Ausgabe durch Wischen aufrufen
To compare the efficacy of desmopressin and placebo in independent geriatric outpatients with nocturnal polyuria (NP).
A prospective, randomized, single-center, national, double blind, placebo-controlled, fixed-dose, parallel group comparative trial was carried out. The study included 110 geriatric outpatients, 55 patients per treatment group using desmopressin acetate nasal spray (strength: 0.1 mg/ml) once daily of 10 μg/spray blast or placebo.
The NP positive geriatric outpatients with >33% nocturnal urine output volume, antidiuretic hormone (ADH) positive or negative were treated over 10 days with intranasal spray in the evening time (7 p.m.), drug or placebo. On day 1 voiding frequency, voiding volumes day and night, serum osmolarity and arginine-vasopressin (AVP) were measured at 7 p.m. On days 2, 5 and 10 creatinine, blood urea nitrogen (bun), blood count and C‑reactive protein (CrP), vena cava diameter and bioimpedance were measured and a structured interview was implemented (voiding frequency, sleeping behavior and subjective and cognitive behavior).
The NP patients showed a mean night voiding volume of 50.60%, 39.21% (n = 102) showed a low AVP level at baseline with no correlation to sodium concentration or voiding frequencies. The primary efficacy criterion, a decrease of the nocturnal voiding frequency during the course of the clinical trial as change from baseline at day 10 (visit 4) was 50% versus 41.40% in the verum versus placebo group, respectively but the differences were not significant. The U‑test showed superiority of AVP-positive NP patients to a positive reaction on desmopressin. Sleeping time hours increased in both groups without significant differences.
In this 10-day clinical trial desmopressin was not proven to be therapeutically superior to placebo with respect to micturition frequency or sleeping hours. Independent geriatric outpatients with decreased ADH levels seemed to respond and benefit from active treatment with desmopressin. The unexpected results in the placebo group may be due to the effect of intensive outpatient care and information on NP outpatients with normal AVP levels.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:
Van Kerrebroeck P, Abrams P, Chaikin D (2002) The standardisation of terminology in nocturia: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 21:179–183 CrossRef
Temml C, Ponholzer A, Gutjahr G, Berger I, Marszalek M, Madersbacher S (2009) Nocturia is an age-independent risk factor for hip-fractures in men. Neurourol Urodyn 28(8):949–952 CrossRef
Booth J, McMillan L (2009) The impact of nocturia on older people—implications for nursing practice. Br J Nursing 18(10):592–596 CrossRef
Scandi Primus G, Madersbacher H, Elnekheli M, Hanzal E, Heidler H, Böhmer F, Mahn W, Struhal G, Klingler C (2006) Differentialdiagnose und Therapie der Nykturie – Konsensusstatement. J Urol Urogynäkol 13(1):21–27
Füsgen I, Weinrebe W (2000) Nocturnal polyuria syndrome. Eur J Geriatr 2(1):30–34
Hernandez FC, Ristol PJ, Estivil E, Miranda Batista JE, Lopez Aramburu MA (2007) Importance of nocturia and its impact on quality of life in patient with benign prostratic hyperplasia. Actas Urol Esp 31:2623–2629
Mattiason A, Abrams P, Van Kerrebroeck P, Walter S (2002) Efficacy of desmopressin in the treatment of nocturia, a double-blind placebo controlled study in men. BJU Int 89:855–862 CrossRef
Asplund R (2008) Nocturia in relation to sleep, health, and medical treatment in the elderly. BJU Int 95(Supplement 1):15–21
- Do independent geriatric outpatients with nocturnal polyuria profit from desmopressin?
Dr. W. Weinrebe
- Springer Medizin